Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma

Abstract

Rituximab is used as a standard of care for follicular lymphoma and is usually administered intravenously. A novel subcutaneous formulation recently showed non-inferior efficacy with similar pharmacokinetic and safety profiles compared to intravenous rituximab in patients with follicular lymphoma. This new approach is promising in terms of comfort for patients and time-saving for hospital staff. To evaluate the real-life economic impact of subcutaneous rituximab as maintenance therapy in patients with follicular lymphoma in real life, we conducted a cost-consequence analysis from the hospital's point of view in three French teaching hospitals. Health-related quality of life (EQ-5D-3L) was investigated as well as patients' and nurses' perception. Compared to intravenous rituximab, subcutaneous administration showed an estimated cost-saving of €109.20 per patient per cycle (p < 0.001), 78.6% of which could be attributed to the rituximab cost. Health-related quality of life showed no significant difference between the two groups despite tendencies for greater pain in the subcutaneous group and greater anxiety in the intravenous group. Thus, subcutaneous rituximab had a favorable pharmacoeconomic profile, with clinical efficacy similar to that of intravenous rituximab. The subcutaneous form was preferred by almost all patients, but further consideration should be given to improve the patients' experience: a dedicated day unit with trained medical, nursing, and pharmaceutical staff could be helpful.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00277-017-3147-y

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 20

Metadata

Authors
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., Tomaré, P., Tournamille, J.-F., Schwiertz, V., Vantard, N., Le Gouill, S., Gyan, E., Salles, G., & Rioufol, C.
Affiliations
  • Lyon 1 Université (FR)
  • Hospices Civils de Lyon (FR)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Centre Hospitalier Universitaire de Tours (FR)
  • Université de Tours (FR)
Corresponding author
Rioufol, Catherine
Venue
Annals of Hematology
Published
2017-10-10
Volume
97
Issue
1
Pages
123-131
ISSN
  • 0939-5555 (ISSN-L)
  • 1432-0584
OpenAlex
W2761412232
Cited by
20
References
24
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2
FWCI
2.95
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Hematology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
follicular lymphoma, maintenance therapy, cost-consequence analysis, pharmacoeconomics, health-related quality of life, patient preferences, nurses' perceptions, hospital cost savings, monoclonal antibodies
MeSH terms
Rituximab, Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, Cross-Sectional Studies, Female, France, Hospitals, Teaching, Humans, Injections, Subcutaneous, Lymphoma, Follicular, Male, Middle Aged, Quality of Life, Drug Costs, Patient Preference, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. https://app.cochat.ai/papers/10.1007/s00277-017-3147-y
The paper
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., Tomaré, P., Tournamille, J.-F., Schwiertz, V., Vantard, N., Le Gouill, S., Gyan, E., Salles, G., & Rioufol, C. (2018). SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-017-3147-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.